Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Theta-burst rTMS in Schizophrenia to Ameliorate Negative and Cognitive Symptoms

NCT: NCT05100888 · COMPLETED

NCT IDNCT05100888
StatusCOMPLETED
Start Date2022-07-11
Completion2026-03-24

Brief Summary

The major target of the study is to confirm the safety and efficacy of our augmented protocol of theta-burst TMS in schizophrenia. Our aim is to confirm the beneficial effects of rTMS treatment on multiple aspects of the disorder such as (1) clinical aspect in terms of PANSS, (2) cognitive aspect such as emotion recognition (ER) and working memory (WM) / distractor filtering (DF) performance, and (3) neurobiology in terms of electrophysiology correlates of ER, WM and DF such as ERPs, event related theta synchronization, resting state theta power, and network connectivity. Response prediction to (theta-burst) TB-rTMS will be the exploratory part of the study.

Frequently Asked Questions

What is Theta-burst rTMS in Schizophrenia to Ameliorate Negative and Cognitive Symptoms?

Theta-burst rTMS in Schizophrenia to Ameliorate Negative and Cognitive Symptoms is a clinical trial registered under NCT05100888. Current status: COMPLETED.

What is the status of NCT05100888?

The current status of NCT05100888 (Theta-burst rTMS in Schizophrenia to Ameliorate Negative and Cognitive Symptoms) is: COMPLETED.

When did Theta-burst rTMS in Schizophrenia to Ameliorate Negative and Cognitive Symptoms start?

Theta-burst rTMS in Schizophrenia to Ameliorate Negative and Cognitive Symptoms started on 2022-07-11.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.